Nascent Biotech

09/05/2024

https://www.accesswire.com/822976/nascent-biotech-receives-an-analyst-opinion-suggesting-that-of-the-company-is-significantly-under-valued

NORTH PALM BEACH, FL / ACCESSWIRE / January 9, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal antibodies focused on treating various cancers, announced today that the Company was featured in an....

02/06/2024

Collaborate to Explore Pritumumab Antibody-Drug Conjugates

NORTH PALM BEACH, FL and NEW YORK, NY / ACCESSWIRE / February 6, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies for the treatment of various cancers and viral infections, announced t...

01/10/2024

Nascent CEO Sean Carrick remarked, "We are pleased to be featured in this independent prospective of Nascent's investment potential. This report underscores our internal conviction that the Company's common stock is presently undervalued."

The report can be viewed on the Company web site at: https://www.nascentbiotech.com/marble-arch-research-what-is-pritumumab-and-how-it-works/

NORTH PALM BEACH, FL / ACCESSWIRE / January 9, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal antibodies focused on treating various cancers, announced today that the Company was featured in an....

12/19/2023

NORTH PALM BEACH, FL / ACCESSWIRE / December 19, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers, is pleased to announce that....

08/22/2023

Nascent Biotech to Begin Phase II Clinical Trials for Brain Cancer

NORTH PALM BEACH, FL / ACCESSWIRE / August 22, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) (

06/07/2023

Nascent Biotech Phase I

“The presentation displayed our Phase I data, which included our safety data at various dose cohorts and early outcomes data, was well received and viewed by interested parties at the conference. In summary, it showed the drug to be very safe at 5 ascending dose cohorts and definitive bioactivity in several patients,” stated Dr. Mini Gill

Nascent Biotech Phase I Clinical Data Presented at the
American Society of Clinical Oncology Annual Meeting
NORTH PALM BEACH, FL, June 7, 2023

Nascent Biotech, Inc. (OTCQB: NBIO) “Nascent
Biotech”, “Nascent”, or the “Company”, a clinical-stage biotechnology Company whose business is focused in therapeutic monoclonal antibody space presented their Phase I Clinical
Data at the American Society of Clinical Oncology (ASCO) meeting in Chicago in a poster presentation.

The abstract may be viewed on the Company web site www.nascentbiotech.com.

The data is also available at https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.2053.

“The presentation displayed our Phase I data, which included our safety data at various dose cohorts and early outcomes data, was well received and viewed by interested parties at the conference. In summary, it showed the drug to be very safe at 5 ascending dose cohorts and definitive bioactivity in several patients,” stated Dr. Mini Gill who presented for the Company.

Nascent Biotech therapeutic antibody Pritumumab (PTB) is a natural human antibody. This monoclonal antibody targets cell surface Vimentin (ectodomain vimentin), shown to be
expressed on the surface of epithelial cancers. PTB is a targeted immunotherapy that binds to the tumor via cell surface vimentin and recruits the host immune system to eliminate cancer
cells.

About Nascent Biotech

Nascent Biotech, Inc. (OTCQB: NBIO) is a clinical-stage biotech company pioneering the development of human monoclonal antibodies to be used in the treatment of various cancers
and viral infections, helping people worldwide. Its products are not yet commercially available.

The Company’s lead candidate, Pritumumab (PTB), is a human monoclonal Antibody (Mab) that is progressing to Phase 2 clinical trials for the treatment of Brain Cancer.

For further information please visit our website

www.nascentbiotech.com.

Forward Looking Safe Harbor Statement

Statements in this press release about our future expectations constitute “forward-looking Statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the
Securities Exchange Act of 1934 and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to
change at any time and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc’s ability to target the
medical professionals; Nascent Biotech Inc’s ability to raise capital; as well as other risks.

Additional information about these and other factors may be described in the Nascent Biotech Inc’s Form 10, filed on May 2, 2015, and future subsequent filings with the Securities and
Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of
this statement or to reflect the occurrence of unanticipated events, except as required by law.

Corporate Contact: Clinical Trials

clinicaltrials@nascentbiotech.com
(800) 301-7883

SOURCE: Nascent Biotech Inc.

05/27/2023

Nascent Biotech Regains Worldwide Rights for Pritumumab

NORTH PALM BEACH, FL / ACCESSWIRE / May 26, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) (

05/14/2023

Your continued support of Nascent Biotech is very much appreciated by the Company’s management. Without it, we could not have achieved the completion of our Phase I Clinical Trial of Pritumumab. This significant milestone allows us to move to another significant milestone – Entering Phase II clinical trials.

We have submitted the clinical plan to the FDA and are anticipating clearance to begin soon. Once clearance is received, we will open the Phase II study as a multi-Center trial enrolling 6 times as many patients as Phase I, demanding more investment dollars. We estimate a need of up to $18.5 million to complete the trial in four tranches of $4.625 million each.

As you are aware, Nascent stock began a steady increase in early 2022 due to favorable announcements regarding the advancement of our Phase I trial, reaching a peak in August 2022. Several factors are believed to have led to this attention to our stock including:

Systematic achievement of trial related advancements.
Opening and completing each cohort in the study.
Favorable outcomes in accordance with the trial objectives.

Dear Shareholder, Your continued support of Nascent Biotech is very much appreciated by the Company’s management. Without it, we could not have achieved the completion of our Phase I Clinical Trial of Pritumumab. This significant milestone allows us to move to another significant milestone – Ent...

05/09/2023

Nascent Biotech to Present Phase I Clinical Data at American Society of Clinical Oncology Annual Meeting

NORTH PALM BEACH, FL / ACCESSWIRE / May 9, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) (

04/18/2023

Nascent Submits Phase 2 Clinical Research Protocol to FDA

for Review and Approval

NORTH PALM BEACH, FL, April 18, 2023 -

Nascent Biotech, Inc. (OTCQB: NBIO) ("Nascent Biotech", "Nascent", or the "Company'), a clinical-stage biotechnology Company whose business is focused in the brain cancer space, announced today that the Protocol for the Phase 2 clinical trials was submitted to the FDA for review and approval.

The review is required for approval to commence the next phase in the development of Pritumumab (“PTB”). Data related to Phase 1 Clinical Research evaluating safety and tolerance for PTB as a treatment for Primary and Metastatic Brain Cancers has also
been submitted to the FDA.

The Company anticipates initial comments from the FDA
approximately 30 days from the date of filing.

PTB is a natural human antibody that binds to Cell surface Vimentin (also referred to as ectodomain vimentin), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy and seek out only cancer cells without damaging healthy cells.

About Nascent Biotech

Nascent Biotech, Inc. (OTCQB: NBIO) is a clinical-stage biotech company pioneering the development of monoclonal antibodies to be used in the treatment of various cancers and viral
infections, helping people worldwide. Its products are not yet commercially available.

The Company's lead candidate, Pritumumab (PTB), is a monoclonal Antibody (Mab) that is being studied in Phase I clinical trials for the treatment of Brain Cancer.

For further information please visit our website www.nascentbiotech.com.

Forward Looking Safe Harbor Statement

Statements in this press release about our future expectations constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the
Securities Exchange Act of 1934 and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to
change at any time and our actual results could differ materially from expected results.

These risks and uncertainties include, without limitation, Nascent Biotech Inc's ability to target the medical professionals; Nascent Biotech Inc's ability to raise capital; as well as other risks.

Additional information about these and other factors may be described in the Nascent Biotech's Form 10, filed on May 2, 2015, and future subsequent filings with the Securities and
Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of
this statement or to reflect the occurrence of unanticipated events, except as required by law.

Corporate Contact:

Sean Carrick | CEO | Nascent Biotech, Inc.
sean.carrick@nascentbiotech.com
Public Relations
EDM Media, LLC
https://edm.media
(800) 301-7883

SOURCE: Nascent Biotech Inc.

EDMMEDIA The Ultimate Branding Partner for Your Business If you want your brand to create a following of loyal customers, skyrocket your conversion rates, and establish yourself as the go-to expert in the industry, you need to ensure your branding is top-notch. But in today’s cut-throat competitio...

02/28/2023

Nascent Announces the Completion of Its Phase1 Clinical Trials

NORTH PALM BEACH, FL, February 28, 2023
-
Nascent Biotech, Inc. (OTCQB: NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company whose business is focused in the brain cancer space, announced today that the Company has completed and closed its Phase I clinical trial evaluating safety and tolerance for Pritumumab (“PTB”) as a treatment for Primary and Metastatic Brain Cancers. Previous announcements shared the end of the enrollment and dosing period of the Phase I trial.

Nascent will continue to collect and evaluate the Clinical data from the Phase I trial as it prepares to submit results to the U.S. FDA for Phase II consideration.

Completing the Phase I trial is a major milestone and Nascent is excited to move toward finalizing plans for Phase II research. Phase I reinforced the companies’ determination and excitement around this unique monoclonal antibody treatment approach and Phase I has shown that it can be given safely at high doses. This is a new pathway toward attacking one of the defining health challenges we face, with longer-term implications that transcend the brain cancer market. We look forward to the opportunity to see our unique R&D platform become a game changer for patients suffering from brain cancer.

PTB is a natural human antibody that binds to Cell surface Vimentin (also referred to as ectodomain vimentin), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy and seek out only cancer cells without damaging healthy cells.

About Nascent Biotech
Nascent Biotech, Inc. (OTCQB: NBIO) is a clinical-stage biotech company pioneering the development of monoclonal antibodies to be used in the treatment of various cancers and viral infections, helping people worldwide. Its products are not yet commercially available. The Company's lead candidate, Pritumumab (PTB), is a monoclonal Antibody (Mab) that is being studied in Phase I clinical trials for the treatment of Brain Cancer.

For further information please visit our website www.nascentbiotech.com.

Forward Looking Safe Harbor Statement
Statements in this press release about our future expectations constitute 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc's ability to target the medical professionals; Nascent Biotech Inc's ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc's Form 10, filed on May 2, 2015, and future subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Corporate Contact

Sean Carrick | CEO | Nascent Biotech, Inc.
sean.carrick@nascentbiotech.com

Public Relations
EDM Media, LLC
https://edm.media
(800) 301-7883

SOURCE: Nascent Biotech Inc.

Start paving the road to your brand's success!

01/25/2023

Nascent Completes Dosing Requirement in Final Cohort of Phase I Clinical Trial

NORTH PALM BEACH, FL January 25, 2023 / - Nascent Biotech, Inc. (OTCQB: NBIO) "Nascent,"Nascent Biotech, or the "Company", a clinical-stage biotechnology Company developing monoclonal antibodies that target various cancer types, announced the completion of the dosing period of their Phase I Clinical Trial evaluating the safety and dose tolerance of Pritumumab (“PTB”) as a treatment for Brain Cancer.

The completion of dosing for the fifth and final Phase I cohort completes safety and dose escalation. The Company will now prepare to submit data and the Phase II Clinical Protocol to the United States Food and Drug Administration (the “FDA”) for evaluation. As the trial remains open for all active and follow-up participants enrolled, we look forward to providing more data on the safety and tolerability of Pritumumab.

PTB is a natural human antibody that binds to Cell surface Vimentin (also referred to as ectodomain vimentin), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy which seeks out only cancer cells while sparing healthy cells.

About Nascent Biotech
Nascent Biotech, Inc is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers. Its products are not commercially available.

For further information please visit our website www.nascentbiotech.com.

Safe Harbor: Statements in this press release about our future expectations constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc's ability to target the medical professionals; Nascent Biotech Inc's ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc's Form 10, filed on October 28, 2014, and future filings with the Securities and
Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of
this statement or to reflect the occurrence of unanticipated events, except as required by law.

Corporate Contact
Sean Carrick | President | CEO | Nascent Biotech, Inc.
772.713.0541 Cell | sean.carrick@nascentbiotech.com

Public Relations
EDM Media, LLC
https://edm.media

SOURCE: Nascent Biotech Inc.

Start paving the road to your brand's success!